Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

J. Johnson, Philip; Qin, Shukui; Park, Joong‐Won; T.P. Poon, Ronnie; Raoul, Jean‐Luc; A. Philip, Philip; Hsu, Chih‐Hung; Hu, Tsung‐Hui; Heo, Jeong; Xu, Jianming; Lu, Ligong; Chao, Yee; Boucher, Éveline; Han, Kwang‐Hyub; Woon Paik, Seung; Alberto Robles-Aviña, Jorge; Kudo, Masatoshi; Yan, Lünan; Sobhonslidsuk, Abhasnee; В. Комов, Д.; Decaens, Thomas; Young Tak, Won; Jeng, Long‐Bin; Liu, David; Ezzeddine, Rana; Walters, Ian; Cheng, Ann‐Lii

doi:10.1200/jco.2012.48.4410

Public

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Published in Journal of Clinical Oncology • Aug 27, 2013

Authors:

Philip J. Johnson

Shukui Qin

Joong‐Won Park

Abstract

PURPOSE: Brivanib is a dual inhibitor of vascular-endothelial growth factor and fibroblast growth factor receptors that are implicated in the pathogenesis of hepatocellular carcinoma (HCC). Our multinational, randomized, double-blind, phase III trial compared brivanib with sorafenib as first-line tr...

Subject

Sorafenib

Medicine

Clinical endpoint

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!